units and supplied to health centres of the States. The Anti snake venom drug is produced in the country in sufficient quantities.

(d) Amrita Institute of Medical Sciences, Cochin, with support from World Health Organisation (WHO) and Government of India organised 'National Snake Bite Conference' in July 2006 to develop a draft National Snake Bite First-aid Protocol for India, a draft National Treatment Protocol for snake bite and to suggest a coordinated research plan for snake bite in India. The organizers are yet to finalize the recommendations of the conference.

New drugs for various diseases

1856. SHRI LALIT SURI: Will the Minister of HEALTH AND FAMILY WELFARE be pleased to state:

(a) whether some of the leading pharmaceutical companies have launched programmes for developing new drugs for curing diseases such as cancer, diabetes, arthritis, etc.;

(b) if so, the names of companies alongwith the products they have developed/are in the process of developing;

(c) whether the necessary statutory clinical trials have been completed, if not, the state at which these trials are being conducted;

(d) what steps are proposed to ensure that no side effects on consumption of such drugs are caused; and

(e) by when these drugs are likely to be ready for use?

THE MINISTER OF HEALTH AND FAMILY WELFARE (DR. ANBUMANI RAMDOSS): (a) Yes Sir. A number of Indian Pharmaceutical companies have launched drug discovery/development programmes. Some of the new drugs being developed are indicated for cancer, diabetes, arthritis etc.

(b) and (c) Information regarding the companies together with products being developed is given in Statement (See below).

(d) and (e) The molecules currently are at various phases of clinical trials (i.e., Phase l/ll), which provide a picture about safety, and efficacy profile of a new molecule. Permission to conduct Phase I clinical trial for molecule developed within the country is given after critical examination of preclinical data (animal toxicity) by a panel of experts. At every stage of

clinical trial, prior approval is required. Only after completion of all phases of clinical trials, approval for manufacture and market is granted. To avoid side effects, Post Marketing Surveillance (PMS) study is further required to be undertaken by the respective Pharmaceutical Companies.

Statement

Names of the companies, products being developed by them and their trial status

Sl.No.	Name of Firm	Name of IND	Category	Status
1	Lupin	LL-4218	Anti-Psoriasis	Phase II Clinical Trial Permission Granted
2	Ranbaxy	RBx7644 (Ranbezolid)	Antibiotic	Phase I Clinical Trial Permission Granted
3	Lupin	LLL-3348 (Desoris)	Anti-Psoriasis	Phase II Clinical Trial Permission Granted
4	Sun	1334H	H1 Receptor Antihistamine	Phase I Clinical Trial Permission Granted
5	Dr. Reddy Labs	DRF 1644 HCI (Camtothecin)	Anticancer	Phase I Clinical Trial Permission Granted
6	Lupin	LL- 4858 (Sudoterb)	Anti-Tubercular	Phase I Clinical Trial Permission Granted
7	Wockhardt	WCK-1152	Antibacterial	Phase 1 Clinical Trial Permission Granted
8	Ranbaxy	RBx 7796 Clafrinast (Earlier RBx 4638)	Anti-Asthmatic	Phase II Clinical Trial Permission Granted
9	Ranbaxy	RBx 11160	Antimalarial	Phase II Clinical Trial Permission Granted
10	Dr. Reddy Labs	DRF 10945	Anti-Dyslipidemic	Phase I Clinical Trial Permission Granted
11	Zydus Cadiia	2YH1	Fir treatment of Hypertipidemia	Phase I Clinical Trial Permission Granted
12	Ranbaxy	RBx 2258 (Parvosin)	Alpha 1 Adrenoreceptor BPH	Phase II Clinical Trial Permission Granted

Sl.No.	Name of Firm	Name of IND	Category	Status
13	Ranbaxy	RBx10558	HMG CoA Reductase Inhibitor having antilipoproteinimic activity	Phase I Clinical Trial Permission Granted
14	Mailadi Drugs	Thrombinase	For Blood Clot Disorders	Phase I Clinical Trial Permission Granted
15	CDRI	CT-1	Anti-Hyperglycemic Agent	Phase I Clinical Trial Permission Granted
16	Dr. Reddy's	2-Deoxy-D-Glucose	In Cerebral Gliomas	Phase III Clinical Trial Permission Granted
17	Dr. Reddy Labs	DRF1042	Anticancer	Phase I Clinical Trial Permission Granted
18	Ranbaxy	RBX9841	For treatment of Overactive bladder & Urinary incontinence	Phase I Clinical Trial Permission Granted
19	Wockhardt	WCK 771	Antibacterial	Phase II Clinical Trial Permission Granted
20	CDRI	CDR 134D-123	Antihyperglycemic	Phase I Clinical Trial Permission Granted
21	Dabur	DRF 7295	Anticancer	Phase II Clinical Trial Permission Granted
22	CDRI	80/574	HypolipidemicAgent	Phase III Clinical Trial Permission Granted
23	Nicholas Piramal	P276-00	Anticancer Agent	Phase I Clinical Trial Permission Granted
24	Zydus Cadila	ZYI 1	Antinflammatory	Phase II Clinical Trial Permission Granted
25	Zydus Cadila	ZYH2	Anti-Dyslipidemic Agent	Phase I Clinical Trial Permission Granted

Measures to reduce the maternal mortality ratio

1857. SHRI B.J. PANDA:
MS. PRAMILA BOHIDAR:

Will the Minister of HEALTH AND FAMILY WELFARE be pleased to state:

(a) whether it is a fact that India has the highest maternal mortality ratio in the world;